Diversified Revenue Streams:
Non‑COVID portfolio momentum across oncology, vaccines, and cardiovascular is contributing, with Eliquis, Prevnar, Vyndaqel, and Seagen‑derived assets cited as growth drivers. This breadth helps offset the normalization of COVID products.
Cost & Operational Efficiency:
Adjusted diluted EPS rose in 2025 versus 2024, attributed to cost realignment and mix. Ongoing cost‑saving and manufacturing optimization programs are intended to support margins through mid‑decade.
Future-Ready Strategy:
Management highlights oncology and next‑generation assets, with Seagen’s ADC platform and pending data/approvals expected to support medium‑term growth. Pipeline catalysts into 2026 position the company for potential re‑acceleration if execution lands as planned.
